The USC Norris Comprehensive Cancer Center (NCCC) is requesting $450,000 per year in Developmental Funds to be used for new investigator support to recruit faculty level scientists in areas of strategic need and to fund innovative pilot projects. These funds will be crucial to our success as we continue to expand the number of investigators supported by the NCCC to fill the newly constructed research space in the Harlyne Norris Research Tower (HNRT). The HNRT is approximately 70% occupied and still has space for an additional 15 investigators. All recruitments are strategic to the NCCC's goals and have been discussed at our leadership retreats, approved by our Cancer Center Leadership Council and Cancer Center Executive Committee and evaluated by our External Advisory Committee. We will allocate our new investigator support annually at the recommendation of the Cancer Center Director and with the advice of our External Advisory Committee and the approval of the Executive Committee. Pilot project funds will be allocated after the review and recommendation for funding by the Leadership Council through the Whittier Initiative. Developmental Funds awarded during the past five years were allocated primarily to the recruitment of new investigators. The remaining portion was used to fund innovative pilot projects and to establish new shared resources.
Developmental Funds allow the NCCC to fund innovative pilot projects and hire additional investigators to perform translational research for the development of more effective prevention, diagnosis, treatment of cancer.
|Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472|
|Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48|
|Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195|
|Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184|
|Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244|
|Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121|
|Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369|
|Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110|
|Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640|
|McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880|
Showing the most recent 10 out of 842 publications